HK1185808A1 - 用於治療癌症的包含威羅菲尼和干擾素的組合療法 - Google Patents

用於治療癌症的包含威羅菲尼和干擾素的組合療法

Info

Publication number
HK1185808A1
HK1185808A1 HK13113352.0A HK13113352A HK1185808A1 HK 1185808 A1 HK1185808 A1 HK 1185808A1 HK 13113352 A HK13113352 A HK 13113352A HK 1185808 A1 HK1185808 A1 HK 1185808A1
Authority
HK
Hong Kong
Prior art keywords
vemurafenib
interferon
cancer
treatment
combination therapy
Prior art date
Application number
HK13113352.0A
Other languages
English (en)
Inventor
Kapil Dhingra
Brian Higgins
Kenneth Kolinsky
Richard J Lee
Brian Lestini
Kathryn E Packman
Fei Su
Original Assignee
霍夫曼-拉羅奇有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 霍夫曼-拉羅奇有限公司 filed Critical 霍夫曼-拉羅奇有限公司
Publication of HK1185808A1 publication Critical patent/HK1185808A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK13113352.0A 2010-12-14 2013-11-29 用於治療癌症的包含威羅菲尼和干擾素的組合療法 HK1185808A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42269010P 2010-12-14 2010-12-14
PCT/EP2011/072408 WO2012080151A1 (en) 2010-12-14 2011-12-12 Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
HK1185808A1 true HK1185808A1 (zh) 2014-02-28

Family

ID=45370460

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13113352.0A HK1185808A1 (zh) 2010-12-14 2013-11-29 用於治療癌症的包含威羅菲尼和干擾素的組合療法

Country Status (13)

Country Link
US (2) US9295669B2 (zh)
EP (1) EP2651414A1 (zh)
JP (1) JP5757544B2 (zh)
KR (2) KR101628448B1 (zh)
CN (1) CN103370066B (zh)
AR (1) AR084233A1 (zh)
BR (1) BR112013014642A2 (zh)
CA (1) CA2819426A1 (zh)
HK (1) HK1185808A1 (zh)
MX (1) MX2013006362A (zh)
RU (1) RU2592983C2 (zh)
TW (1) TWI468161B (zh)
WO (1) WO2012080151A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
ES2743427T3 (es) 2012-08-17 2020-02-19 Hoffmann La Roche Politerapias para melanoma que comprenden administrar cobimetinib y vemurafinib
ES2642162T3 (es) * 2015-03-26 2017-11-15 Ratiopharm Gmbh Composición que comprende vemurafenib y HPMC-AS
WO2017004421A1 (en) * 2015-06-30 2017-01-05 The Trustees Of The University Of Pennsylvania Resiquimod topical and injectable compositions for the treatment of neoplastic skin conditions
NZ755835A (en) 2017-01-17 2023-12-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN112245570A (zh) * 2019-07-22 2021-01-22 厦门特宝生物工程股份有限公司 一种基于干扰素的疾病治疗方法
AU2022210179A1 (en) * 2021-01-21 2023-09-07 Biosteed Gene Transformation Tech. Co., Ltd. Interferon-based cancer treatment method, and pharmaceutical combination

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516807A (en) 1994-10-25 1996-05-14 Warner-Lambert Company Method for treating vascular proliferative disorders following balloon angioplasty
ATE330600T1 (de) 2000-01-26 2006-07-15 Schering Corp Kombinationspräparat zur krebstherapie
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
NZ522766A (en) 2000-05-15 2005-09-30 Celgene Corp Compositions and methods for the treatment of colorectal cancer with irinotecan and thalidomide to reduce side effects
RU2003113538A (ru) 2000-10-13 2004-11-10 Вайон Фармасьютикалз, Инк. (Us) Модифицированные пролекарственные формы ap/amp
RU2179859C1 (ru) 2001-05-22 2002-02-27 Центральный научно-исследовательский рентгено-радиологический институт Способ лечения почечно-клеточного рака
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US20080193445A1 (en) 2002-01-18 2008-08-14 Liliane Goetsch Novel anti-IGF-IR antibodies and uses thereof
US20050176740A1 (en) 2002-04-08 2005-08-11 Spector Neil L. Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
JP2006520368A (ja) 2003-03-19 2006-09-07 アレス トレーディング ソシエテ アノニム アルツハイマー病の治療
BRPI0409484A (pt) 2003-04-17 2006-05-02 Ares Trading Sa interferon beta em sìndrome respiratória aguda severa (sars)
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
CA2550361C (en) 2003-12-19 2014-04-29 Prabha Ibrahim Compounds and methods for development of ret modulators
US20070281041A1 (en) 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
TW200533339A (en) 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
CA2566971A1 (en) 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with irinotecan (cpt-11) and an egfr-inhibitor
KR100851271B1 (ko) 2004-06-03 2008-08-08 에프. 호프만-라 로슈 아게 이리노테칸 （ｃｐｔ-１１） 및 ｅｇｆｒ-억제제를 이용한치료
EP1785484B1 (en) 2004-06-30 2011-06-01 Japan Science and Technology Agency Oligonucleotide inhibiting tumor cell proliferation and method therefor
KR20080003422A (ko) 2005-04-14 2008-01-07 메르크 파텐트 게엠베하 종양 조직 내의 ｅｇｆｒ 유전자의 증가된 복제수에 기초한항-ｅｇｆｒ 항체 치료
EP1917019A2 (en) 2005-05-03 2008-05-07 Biopolymer Engineering, Inc. Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection
US20060257400A1 (en) 2005-05-13 2006-11-16 Bristol-Myers Squibb Company Combination therapy
BRPI0611863B1 (pt) 2005-06-22 2021-11-23 Plexxikon, Inc Composto, bem como composição e kit compreendendo o mesmo, composto intermediário na preparação do mesmo, método para tratamento e uso do mesmo
EP2130822A1 (en) 2005-12-01 2009-12-09 F. Hoffmann-La Roche AG 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents
JP2009535372A (ja) 2006-05-03 2009-10-01 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 抗ｅｄｂフィブロネクチンドメイン抗体ｌ１９−ｓｉｐ及び抗−ｅｇｆｒ−抗体の組合せ
CA2662508A1 (en) 2006-09-19 2008-07-10 Novartis Ag Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
TW200901975A (en) 2007-03-05 2009-01-16 Kyowa Hakko Kogyo Kk Pharmaceutical composition
JP5563455B2 (ja) 2007-08-01 2014-07-30 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｌｒ９の新規な合成アゴニスト
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
MY172424A (en) 2009-04-03 2019-11-25 Hoffmann La Roche Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
AU2010236606A1 (en) 2009-04-14 2011-11-03 Merck Sharp & Dohme Corp. Interferon-alfa sensitivity biomarkers
MX2011012311A (es) 2009-05-21 2011-12-14 Schering Corp Marcadores geneticos asociados con la respuesta al interferon alfa.
CA2771369A1 (en) 2009-08-24 2011-03-10 Genentech, Inc. Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
JP2013538856A (ja) 2010-10-01 2013-10-17 バイオジェン・アイデック・エムエイ・インコーポレイテッド 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders

Also Published As

Publication number Publication date
AR084233A1 (es) 2013-05-02
US20160256529A1 (en) 2016-09-08
US20120148533A1 (en) 2012-06-14
CA2819426A1 (en) 2012-06-21
TW201300107A (zh) 2013-01-01
US9295669B2 (en) 2016-03-29
EP2651414A1 (en) 2013-10-23
CN103370066A (zh) 2013-10-23
WO2012080151A1 (en) 2012-06-21
TWI468161B (zh) 2015-01-11
CN103370066B (zh) 2015-09-09
JP5757544B2 (ja) 2015-07-29
RU2592983C2 (ru) 2016-07-27
MX2013006362A (es) 2013-07-30
JP2013545772A (ja) 2013-12-26
KR20160031039A (ko) 2016-03-21
RU2013130926A (ru) 2015-01-20
KR101628448B1 (ko) 2016-06-08
BR112013014642A2 (pt) 2020-08-11
KR20130092617A (ko) 2013-08-20

Similar Documents

Publication Publication Date Title
HK1204914A1 (zh) 用於治療病毒感染的包含替諾福韋艾拉酚胺半反丁烯二酸鹽和可比西他的組合療法
HK1185808A1 (zh) 用於治療癌症的包含威羅菲尼和干擾素的組合療法
ZA201309241B (en) Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
IL222006A (en) Pyrulobenzodiazepine conjugates and their use in medicine
PT3042910T (pt) 2'-espiro-nucleósidos para utilização na terapia da hepatite c
ZA201206425B (en) Use of erbb3 inhibitors in the treatment of treatment of triple negative and basal-like breast cancers
GB0921596D0 (en) Particles for the treatment of cancer in combination with radiotherapy
IL223241A0 (en) Cysteamine derivatives and their use in the treatment of nash
ZA200906765B (en) Combination therapies comprising quinoxaline inhibitors of P13K-Alpha for use in the treatment of cancer
HK1209792A1 (zh) 標誌物在診斷和治療前列腺癌中的用途
IL228847A0 (en) il1r1 inhibitors and their use in cancer treatment
EP2651894A4 (en) THIOSEMICARBAZONE COMPOUNDS FOR CANCER TREATMENT
ZA201209452B (en) Gold complexes for use in the treatment of cancer
EP2575863A4 (en) USE OF SPARC MICROENVIRONMENT SIGNATURE IN THE TREATMENT OF CANCER
HK1203430A1 (zh) 可用於治療炎症和癌症的二芳基磺酰胺
IL236321A0 (en) Combined treatment for cancer and immunosuppression
EP2744786A4 (en) SUBSTITUTED 2-IMIDAZOLIDINONE AND 2-IMIDAZOLONE AND THEIR USE IN THE TREATMENT OF CANCER
ZA201202657B (en) Use of the sparc microenvironment signature in the treatment of cancer
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
HK1214771A1 (zh) 用於治療皮膚病的製劑
EP2404611A4 (en) Peptide for the prophylactic or therapeutic treatment of skin tumors, in the initial stages
EP2336108A4 (en) TRIPYRROL-OCTAARGININE HYBRID COMPOUNDS AND USE THEREOF AS A MEDICAMENT FOR TREATING CANCER AND MICROBIAL DISEASES
HUP1000688A2 (en) Use of trifluoro-phthalimides in the treatment of cancer
GB201021425D0 (en) Drug composition and its use in therapy

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20191214